LAUSR

Key Points Question Is very-low-dose edoxaban (15 mg/day) beneficial across frailty status among very elderly Japanese patients with atrial fibrillation considered ineligible for standard dose oral anticoagulants because of their high bleeding risk? Findings In this cohort study of 944 patients using data from the ELDERCARE-AF trial, very-low-dose edoxaban was associated with lower incidence of stroke or systemic embolism consistently across frailty status, including each assessment parameter, with a numerically higher risk of major or clinically relevant nonmajor bleeding. Meaning These findings suggest that edoxaban (15 mg) is superior to placebo in preventing stroke or systemic embolism in very elderly patients with atrial fibrillation, regardless of frailty status, and may be a suitable treatment option for these patients.